Mounjaro

Adjunct to diet & exercise in adults w/ insufficiently controlled type 2 DM as monotherapy when metformin is considered inappropriate due to intolerance or contraindications, or in addition to other medicinal products for diabetes. Adjunct to reduced-calorie diet & increased physical activity for wt management, including wt loss & maintenance in adults w/ initial BMI of ≥30 kg/m² (obesity) or ≥27 to <30 kg/m² (overwt) in the presence of at least one wt-related comorbid condition (eg, HTN, dyslipidaemia, obstructive sleep apnoea, CV disease, prediabetes, or type 2 DM).

SC Inj in the abdomen, thigh or upper arm. Initially 2.5 mg once wkly, increased to 5 mg once wkly after 4 wk. May increase dose in 2.5 mg increments after min of 4 wk on current dose. Recommended maintenance dose: 5 mg, 10 mg & 15 mg. Max dose: 15 mg once wkly.

May be taken with or without food.

Hypersensitivity.

Discontinue treatment if pancreatitis is suspected. Not to be restarted if pancreatitis diagnosis is confirmed. Increased risk of hypoglycemia in combination w/ an insulin secretagogue (eg, sulphonylurea) or insulin. Acute pancreatitis. Nausea, vomiting & diarrhoea leading to dehydration which may further lead to renal function deterioration including acute renal failure. Avoid fluid depletion & electrolyte disturbances especially in the elderly. Patients w/ severe GI disease including severe gastroparesis; non-proliferative diabetic retinopathy requiring acute therapy, proliferative diabetic retinopathy or diabetic macular oedema; history of pancreatitis. Contains benzyl alcohol. May affect ability to drive & use machines when used in combination w/ sulphonylurea or insulin. Severe hepatic or renal impairment & ESRD. Women of childbearing potential should use effective contraception while on treatment. Discontinue treatment if pregnancy occurs; at least 1 mth before planned pregnancy. Not recommended during pregnancy & in women of childbearing potential not using contraception. Lactation. Childn <18 yr.

Hypoglycaemia when used w/ sulphonylurea or insulin; nausea, diarrhea, vomiting, abdominal pain, constipation. Hypersensitivity reactions; hypoglycaemia when used w/ metformin & SGLT2 inhibitor, decreased appetite; dizziness; hypotension; dyspepsia, abdominal distention, eructation, flatulence, GERD; hair loss; fatigue, inj site reactions; increased heart rate, lipase, amylase & blood calcitonin.

Potential to impact the absorption rate of concomitantly administered oral medicinal products. Monitor patients on oral medicinal products w/ narrow therapeutic index (eg, warfarin, digoxin), especially at initiation of tirzepatide treatment & following dose increase. Consider risk of delayed effect in oral medicinal products for which a rapid onset of effect is of importance.

Antidiabetic Agents / Anti-Obesity Agents

A10BX16 - tirzepatide ; Belongs to the class of other blood glucose lowering drugs excluding insulins. Used in the treatment of diabetes.

S